Industry

DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) today announced it submitted a planning application to expand its development and manufacturing facility in Waterford, Ireland to add new drug substance biologics development and manufacturing capabilities. The planned facility would expand Horizon’s footprint, adding approximately 320,000 square feet to its current 44,000 square foot drug product (fill-finish) biologics … [Read more…]

First in-vivo data for ONKT102, a fully human, optimized affinity CD38 CAR-NK cell therapy Data showed potent anti-tumor activity in-vitro and in-vivo of cord-derived ONKT102 in a CD38 positive tumor model of multiple myeloma Poster presented at the International Myeloma Society 2022, 25-27 August 2022, Los Angeles, USA by CSO Prof. Michael O’Dwyer GALWAY, Ireland … [Read more…]

Teva Pharmaceuticals to commercialize the product in Europe Age related macular degeneration (AMD) affects around 67 million people in Europe and is a leading cause of blindness for working age adults with uncontrolled diabetes1 and the most common cause of blindness in developed countries2. Ranivisio (ranibizumab) will be the first ophthalmology biosimilar of Lucentis to … [Read more…]

Data from the ETNA-AF-Europe Registry provide insights on edoxaban in routine clinical practice in patient subpopulations including those who are frail, with heart failure or insulin-dependent diabetes1,2,3 Latest findings presented at the European Society of Cardiology (ESC) Congress 2022 add to the wealth of edoxaban data reinforcing its safety and effectiveness in routine care across … [Read more…]

The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in the prevention of stroke events in patients with atrial fibrillation as well as patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack1,2 OCEANIC-AF and OCEANIC-STROKE are expected to enroll up to 30,000 patients in over … [Read more…]

~30% relative risk reduction seen in symptomatic ischemic strokes in three milvexian arms compared to placebo; dose response not observed for primary study objective No fatal bleeding and no increase in symptomatic intracranial hemorrhage observed in patients treated with milvexian, even with all patients receiving 21 days of background dual antiplatelet therapy followed by single … [Read more…]

Pre-specified pooled analysis from Phase III trials demonstrated reduction in CV death by 14% and reduction in death from any cause by 10% in patients with heart failure irrespective of ejection fraction First heart failure medication to demonstrate mortality benefit across the full ejection fraction range Results being presented at the European Society of Cardiology … [Read more…]

Results presented at European Society of Cardiology Congress 2022, and published in New England Journal of Medicine Data extend the clinically meaningful benefits of FARXIGA in patients with heart failure regardless of ejection fraction Heart failure is a chronic, progressive disease impacting nearly 64 million people WILMINGTON, Del.–(BUSINESS WIRE)–Detailed results from the DELIVER Phase III … [Read more…]

Global Leader in Infection Prevention to Showcase Innovative Healthcare Products that Clean, Protect, and Test BOSTON & LONDON–(BUSINESS WIRE)–2San, a trusted global Tier 1 supplier of high-quality innovative healthcare products and solutions that Clean, Protect, and Test, will exhibit for the first time at the National Association of Chain Drug Stores (NACDS) Total Store Expo … [Read more…]

TORONTO–(BUSINESS WIRE)–NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, announced today that, in relation to the executive changes announced on July 25, 2022, a grant of 965,000 stock options (“Options”) to certain officers of the Company at an exercise price of $0.30 … [Read more…]